Revolutionizing indoor health through light

Investor presentation

LEGAL NOTICE

Important disclosures.

FORWARD-LOOKING INFORMATION

This presentation contains "forward-looking information" within the meaning of applicable Canadian securities laws and "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking, including, without limitation, statements regarding product development plans, regulatory pathways, market opportunity, manufacturing capacity, partnership prospects, Far-UVC commercialization timelines, and the company's pro-forma capital structure following listing on the TSX Venture Exchange.

Forward-looking statements are based on assumptions and estimates management believes reasonable as of the date hereof. Actual results may differ materially due to risks including, but not limited to, regulatory delays, product development risk, competitive pressure, supply-chain disruption, customer adoption rates, capital market conditions, and the risks set forth in the company's continuous disclosure record on SEDAR+. The company undertakes no obligation to update forward-looking statements except as required by law.

NON-IFRS MEASURES

INDUSTRY & MARKET DATA

Market data, statistics, and forecasts cited herein are derived from third-party sources, internal estimates, and management assumptions. While the company believes such information to be reliable, it has not been independently verified. Statements regarding market size, penetration rates, competitive positioning, and the performance of competing products reflect management's views and may not be representative of actual outcomes. Independent third-party validation referenced reflects testing conducted under specified laboratory conditions; real-world performance may vary.

THE PROBLEM

Indoor spaces are making people sick, and the world is finally demanding a solution.

THE COST OF INACTION

  • 10M+ Hospital-acquired infections every year.
  • $100 B+ ANNUAL BURDEN

WHY NOW FOUR CONVERGING FORCES

  1. Indoor air is a health crisis: HAIs kill more people than car accidents. Indoor transmission drives pandemic economics.
  2. Standards are tightening: WHO & CDC raised clean-air targets in 2023-24. ASHRAE 241 sets new clean-airflow rules.
  3. Liability drives urgency: 7 certified class actions/200+ facilities/$100M+ active claims. Procurement converting to signed contracts.

OUR TECHNOLOGY PLATFORM

Two pillars of innovation.

Comprehensive lighting solutions that save energy and protect health through our mastery of the light spectrum.

UPPER-ROOM GUV

Proven upper-room germicidal UV. Health Canada registered for human-safe pathogen elimination in occupied spaces. Validated by the University of Leeds as the best-performing UV device tested in their aerobiology chamber.

  • 99.7 % KILL RATE

FAR-UVC

100% MADE IN CANADA

Human-safe disinfection at scale.

Breakthrough 216 nm Far-UVC, IP owned outright by Illumisoft, not licensed excimer. Cannot penetrate human skin or eyes; unlocks continuous disinfection in occupied spaces conventional GUV physically cannot reach.

THE TECHNOLOGY

The science of UVC is proven. The problem, until now, was human safety.

Short-wavelength UV breaks apart the DNA and RNA of viruses, bacteria, and fungi. There is no chemical residue, and no resistance can develop; pathogens cannot evolve around physics.

MECHANISM

Mounted above head-height so occupants never encounter the direct beam. Ceiling fans continuously draw indoor air through the germicidal field, delivering 1,994 equivalent air changes per hour.

  • Upper-room germicidal UV.
  • Far-UVC, human-safe disinfection.

At 216 nm the light still kills pathogens, but cannot penetrate human skin or the tear layer of the eye. Solid-state, 70× more powerful than excimer, unlocks continuous disinfection in occupied spaces.

PRODUCT PORTFOLIO

Our product family.

ECOWing

Diffused LED lighting. Industry-leading commercial LED retrofit; 34 of Top 50 DLC products globally, with patented optical film that eliminates glare without sacrificing efficiency.

  • 167 Im/W PEAK EFFICACY
  • 60-75% ENERGY SAVINGS
  • 50,000 h LIFESPAN

SaniLume

99.7% PATHOGEN KILL 750 ft² COVERAGE 24 days HOSPITAL PAYBACK

Far-UVC at 216 nm, 70× more powerful than excimer alternatives at one-fifth the cost. Proprietary nanoengineered technology, safe for continuous human exposure.

SaniLux

70x MORE POWERFUL 216 nm PEAK EMISSION

ACTIVE REVENUE

HEALTH CANADA REGISTERED

The most effective upper-room germicidal UV device in the market. Independently validated at the University of Leeds aerobiology chamber, 2022.

  • 99.7% ELIMINATION RATE
  • 201-1,994 EQUIV. AIR CHANGES / HR
  • 750 ft² COVERAGE

INDEPENDENT VALIDATION: UNIVERSITY OF LEEDS

The most powerful upper-room GUV device on the market. The best performing UV device that has been tested in the aerobiology chamber at the University of Leeds to date.

  • 99.7% PSEUDOMONAS AERUGINOSA
  • 99.2% STAPHYLOCOCCUS AUREUS

COMMERCIAL CASE

Validated economics. Mandatory demand.

Lives saved annually $47.7B

Program investment: $3.2B

COMING SOON FAR-UVC / 216 NM

A fundamental shift, not an increment.

Proprietary 216 nm solid-state Far-UVC. IP owned outright by Illumisoft, not licensed excimer.

SANI-LUX

70x MORE POWERFUL

Human-safe at 216 nm; cannot penetrate skin or eyes. Unlocks continuous disinfection in occupied spaces.

TECHNOLOGY ADVANTAGE

SaniLux vs. conventional Far-UVC, every competitor licenses excimer from one Japanese supplier.

METRIC EXCIMER/USHIO/R-ZERO ILLUMISOFT SANILUX ADVANTAGE
Power output Milliwatt range Watt range/70× higher 70×
Kill time 60-90 min per cycle Under 1 min(at peak)* 70-90× faster
Unit price $1,000-$5,000+ ~$350 target 66-77% lower
Product lifespan ~1,000 hours 10,000+ hours 10× longer
Aviation / transit No / insufficient power Yes / market-creating $200B+ new

INDUSTRY VALIDATION / BLUEPRINT BIOSECURITY

Why Far-UVC is the future of indoor air.

Independent assessment by Blueprint Biosecurity, showing significant advances in airborne disease prevention.

THE BLUEPRINT'S THREE-PART ARGUMENT

  1. Categorically different from conventional UV.
  2. Cost-benefit profile is exceptional.

MARKET OPPORTUNITY

$248B global market/bottom-up path to $100M revenue.

TRACTION / TRUSTED BY INDUSTRY LEADERS

In partnership with Health Canada to help establish Workplace 3.0 standards for Federal buildings.

GO-TO-MARKET & SCALE

Canada first. The world follows the standard.

ABOUT ILLUMISOFT

A Canadian photonics company focused on implementing revolutionary lighting solutions for improved indoor health.

CAPITAL STRUCTURE

  • Claranova shares: 22,261,805
  • Gstaad post-consolidation: 1,881,667

INVESTMENT THESIS Six reasons. Why illumisoft.

  1. Mandatory market, today.
  2. Validated performance.
  3. Unpriced $200B+ market potential.
  4. Backed by mission-aligned backers.
  5. Two existential tailwinds.

Proven technology. Mandatory market. Generational entry point.

WEB: illumisoft.com
TICKER: TSX-V : UVC